Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

Loading...

Supplementary Data — Tixagevimab/cilgavimab for COVID-19: real-time meta analysis of 12 studies

@CovidAnalysis, September 2023
https://c19early.org/tcmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ TACKLE Montgom.. (DB RCT) 0% 1.00 [0.32-3.07] death 6/452 6/451 Improvement, RR [CI] Treatment Control TACKLE Montgom.. (DB RCT) 50% 0.50 [0.29-0.86] severe case 18/407 37/415 TACKLE Montgom.. (DB RCT) 57% 0.43 [0.25-0.75] hosp. 17/413 40/421 Lombardi -368% 4.68 [0.31-71.6] death 1/19 1/89 OT​1 Lombardi 33% 0.67 [0.09-5.13] hosp. 1/19 7/89 OT​1 Lombardi -24% 1.24 [0.90-1.70] viral+ 14/19 53/89 OT​1 ACTIV-3-TICO Holland (DB RCT) 30% 0.70 [0.50-0.97] death 61/710 86/707 ACTIV-3-TICO Holland (DB RCT) 7% 0.93 [0.83-1.03] no recov. 710 (n) 707 (n) FDA (DB RCT) 40% 0.60 [0.35-1.03] symp. case 28/749 23/372 FDA (DB RCT) 33% 0.67 [0.36-1.24] symp. case 23/749 17/372 PROVENT Levin (DB RCT) 86% 0.14 [0.01-2.98] death 0/3,441 2/1,731 PROVENT Levin (DB RCT) 82% 0.18 [0.09-0.35] symp. case 11/3,441 31/1,731 PROVENT Levin (DB RCT) 76% 0.24 [0.10-0.55] symp. case 8/3,441 17/1,731 Young-Xu (PSM) 64% 0.36 [0.18-0.73] death 1,733 (n) 6,354 (n) Immunocompromised Young-Xu (PSM) 69% 0.31 [0.18-0.53] cases/death/hosp. 17/1,733 206/6,354 Immunocompromised Young-Xu (PSM) 87% 0.13 [0.02-0.99] hosp. 1,733 (n) 6,354 (n) Immunocompromised Young-Xu (PSM) 66% 0.34 [0.13-0.87] cases 1,733 (n) 6,354 (n) Immunocompromised Kertes 92% 0.08 [0.01-0.54] death/hosp. 1/825 63/4,299 Immunocompromised Kertes 47% 0.53 [0.32-0.85] cases 29/825 308/4,299 Immunocompromised Najjar-Debbiny 59% 0.41 [0.19-0.89] hosp. 72/703 377/2,812 Najjar-Debbiny 25% 0.75 [0.58-0.96] cases 72/703 377/2,812 Levin (DB RCT) 75% 0.25 [0.01-6.10] severe case 0/749 1/372 Levin (DB RCT) 42% 0.58 [0.34-1.00] symp. case 27/749 23/372 Levin (DB RCT) 33% 0.67 [0.36-1.24] symp. case 23/749 17/372 Sindu (PSM) -1% 1.01 [0.14-7.21] death 2/17 2/17 Sindu (PSM) -96% 1.96 [0.18-21.6] ventilation n/a n/a Sindu (PSM) -210% 3.10 [0.32-29.8] ICU n/a n/a Sindu (PSM) 53% 0.47 [0.16-1.40] hosp. n/a n/a Sindu 29% 0.71 [0.46-1.11] symp. case 24/203 57/343 Din 19% 0.81 [0.32-2.04] hosp. 5/23 11/41 Desai 12% 0.88 [0.33-2.35] hosp. 391 (n) 391 (n) Desai -35% 1.35 [0.87-2.10] cases 391 (n) 391 (n) Tixagevimab/cilgavimab COVID-19 outcomes c19early.org Sep 2023 1 OT: comparison with other treatment Favors tixagevimab/ci.. Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit